Daily High to Daily Low: Is It Safe to Buy bluebird bio Inc. (BLUE)? – News Heater
Home  »  Hot Stocks   »  Daily High to Daily Low: Is It Safe to Buy bluebir...

Daily High to Daily Low: Is It Safe to Buy bluebird bio Inc. (BLUE)?

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

bluebird bio Inc. (NASDAQ:BLUE) went up by 0.28% from its latest closing price compared to the recent 1-year high of $34.75. The company’s stock price has collected -4.86% of loss in the last five trading sessions. Press Release reported on 11/22/21 that bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with -thalassemia Who Require Regular Red Blood Cell Transfusions

Is It Worth Investing in bluebird bio Inc. (NASDAQ :BLUE) Right Now?

Plus, the 36-month beta value for BLUE is at 1.51. Opinions of the stock are interesting as 3 analysts out of 17 who provided ratings for bluebird bio Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 12 rated it as “hold,” and 2 as “sell.”


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The average price from analysts is $12.72, which is $3.53 above the current price. BLUE currently public float of 66.72M and currently shorts hold a 11.81% ratio of that float. Today, the average trading volume of BLUE was 1.81M shares.

BLUE’s Market Performance

BLUE stocks went down by -4.86% for the week, with a monthly drop of -20.66% and a quarterly performance of -7.30%, while its annual performance rate touched -61.02%. The volatility ratio for the week stands at 5.84% while the volatility levels for the past 30 days are set at 7.94% for bluebird bio Inc.. The simple moving average for the period of the last 20 days is -15.64% for BLUE stocks with a simple moving average of -35.80% for the last 200 days.

Analysts’ Opinion of BLUE

Many brokerage firms have already submitted their reports for BLUE stocks, with Wells Fargo repeating the rating for BLUE by listing it as a “Equal Weight.” The predicted price for BLUE in the upcoming period, according to Wells Fargo is $16 based on the research report published on November 08th of the current year 2021.

Wedbush, on the other hand, stated in their research note that they expect to see BLUE reach a price target of $11, previously predicting the price at $22. The rating they have provided for BLUE stocks is “Neutral” according to the report published on November 08th, 2021.

RBC Capital Mkts gave a rating of “Sector Perform” to BLUE, setting the target price at $14 in the report published on November 08th of the current year.

BLUE Trading at -14.94% from the 50-Day Moving Average

After a stumble in the market that brought BLUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.04% of loss for the given period.

Volatility was left at 7.94%, however, over the last 30 days, the volatility rate increased by 5.84%, as shares sank -51.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.55% lower at present.

During the last 5 trading sessions, BLUE fell by -4.86%, which changed the moving average for the period of 200-days by -76.87% in comparison to the 20-day moving average, which settled at $15.15. In addition, bluebird bio Inc. saw -61.59% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BLUE starting from Obenshain Andrew, who sale 511 shares at the price of $30.75 back on Jun 04. After this action, Obenshain Andrew now owns 39,597 shares of bluebird bio Inc., valued at $15,715 using the latest closing price.

Gregory Philip D, the Chief Scientific Officer of bluebird bio Inc., sale 39 shares at $30.15 during a trade that took place back on May 03, which means that Gregory Philip D is holding 46,829 shares at $1,176 based on the most recent closing price.

Stock Fundamentals for BLUE

Current profitability levels for the company are sitting at:

  • -251.07 for the present operating margin
  • +90.13 for the gross margin

The net margin for bluebird bio Inc. stands at -246.75. The total capital return value is set at -41.63, while invested capital returns managed to touch -41.54. Equity return is now at value -78.40, with -55.60 for asset returns.

Based on bluebird bio Inc. (BLUE), the company’s capital structure generated 14.24 points at debt to equity in total, while total debt to capital is 12.47. Total debt to assets is 10.84, with long-term debt to equity ratio resting at 12.40. Finally, the long-term debt to capital ratio is 10.85.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of -3.83, with the company’s debt to enterprise value settled at 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.97.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

A Lesson to Learn: Deere & Company (DE)

Deere & Company (NYSE:DE) went up by 2.66% from its latest closing price compared to the recent 1-year high of $400.34. The company’s stock price

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam